At 1PM UTC December 2nd, honorly invited by World Health Organization (WHO), BravoVax attended the Dedicated Webinar for BravoVax COVID-19 Vaccine, formally introducing its COVID-19 vaccine, BravoCoVac®, to the NRAs across the world!
As a start-up R&D company, BravoVax received sustainable attention from WHO by the superior antigen design, comprehensive process development and encouraging animal study data of its novel COVID-19 vaccine.
Dr. Wu Ke, CEO of BravoVax, gave a speech on the Webinar, introducing the product design route, preclinical study and stability study data of BravoCoVac®, and our external consultant, Dr. Ben Greener, presented the Clinical Development Plans for BravoCoVac®, winning positive feedbacks from the participants. Dr. Wu and his team as well as external consultant responded to all the online and on-site questions from the regulatory officers.
Ever since the establishment of BravoVax, it has a vision to be a global supplier of high-quality and affordable vaccines. Following this dream, we make great endeavors to develop the COVID-19 vaccine, expecting more people in the world could get access to our novel vaccines, thus contributing to the control of the pandemic!